Draft Guidance on Midodrine Hydrochloride

This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Midodrine Hydrochloride

Form/Route: Tablets/Oral

Recommended studies: 2 Studies

1. Type of study: Fasting
   Design: Single-dose, two-way crossover in-vivo
   Strength: 5 mg
   Subjects: Normal healthy males and females, general population. Females should not be of childbearing potential.
   Additional comments: Due to safety reasons, the 5 mg dose is more appropriate for a single dose in vivo bioequivalence study in subjects.

2. Type of study: Fed
   Design: Single-dose, two-way crossover in-vivo
   Strength: 5 mg
   Subjects: Normal healthy males and females, general population. Females should not be of childbearing potential.
   Additional Comments: Please see comment above.

Analytes to measure (in appropriate biological fluid): Midodrine in plasma.

Bioequivalence based on (90% CI): Midodrine

Waiver request of in-vivo testing: 2.5 mg and 10 mg based on (i) acceptable bioequivalence studies on the 5 mg strength, (ii) acceptable dissolution testing across all strengths, and (iii) proportional similarity in the formulations across all strengths.

Dissolution test method and sampling times:

Please note that a Dissolution Methods Database is available to the public at the OGD website at http://www.fda.gov/cder/ogd/index.htm. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.

Recommended Aug 2008